{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:22:34Z","timestamp":1794525754943,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Partially supported by an Investigator-Initiated Research grant from Shire International GmbH, a Takeda company.","award":["IIR-ITA-001466"],"award-info":[{"award-number":["IIR-ITA-001466"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fabry disease (FD) is an X-linked lysosomal storage disorder, caused by deficient activity of the alpha-galactosidase A enzyme leading to progressive and multisystemic accumulation of globotriaosylceramide. Recent data point toward oxidative stress signalling which could play an important role in both pathophysiology and disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We have examined oxidative stress biomarkers [Advanced Oxidation Protein Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), thiolic groups] in blood samples from 60 patients and 77 healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      AOPP levels were higher in patients than in controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001) and patients presented decreased levels of antioxidant defences (FRAP and thiols) with respect to controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001). In a small group of eight treatment-na\u00efve subjects with FD-related mutations, we found altered levels of oxidative stress parameters and incipient signs of organ damage despite normal lyso-Gb3 levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Oxidative stress occurs in FD in both treated and na\u00efve patients, highlighting the need of further research in oxidative stress-targeted therapies. Furthermore, we found that oxidative stress biomarkers may represent early markers of disease in treatment-na\u00efve patients with a potential role in helping interpretation of FD-related mutations and time to treatment decision.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-020-10044-w","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T10:04:09Z","timestamp":1595844249000},"page":"3741-3752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Oxidative stress biomarkers in Fabry disease: is there a room for them?"],"prefix":"10.1007","volume":"267","author":[{"given":"C.","family":"Simoncini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Torri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Montano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gruosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tuttolomondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Simonetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Salviati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Vicenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Girelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Concolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sestito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2738-8562","authenticated-orcid":false,"given":"Michelangelo","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"key":"10044_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP (2010) Fabry disease. Orph J Rare Dis 5:30","journal-title":"Orph J Rare Dis"},{"issue":"5","key":"10044_CR2","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT et al (2017) Characterization of classical and nonclassical fabry disease: A multicenter study. J Am Soc Nephrol 28(5):1631\u20131641","journal-title":"J Am Soc Nephrol"},{"issue":"13","key":"10044_CR3","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1161\/hc3801.096352","volume":"104","author":"DF Moore","year":"2011","unstructured":"Moore DF, Scott LTC, Gladwin MT, Altarescu G, Kaneski C, Suzuki K et al (2011) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in fabry disease: reversal by enzyme replacement therapy. Circulation 104(13):1506\u20131512","journal-title":"Circulation"},{"issue":"4","key":"10044_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/jmri.20162","volume":"20","author":"DF Moore","year":"2004","unstructured":"Moore DF, Ye F, Brennan M-L, Gupta S, Barshop BA, Steiner RD, et al (2004) Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging 20(4):674\u2013683","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"10044_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","volume":"95","author":"J-S Shen","year":"2008","unstructured":"Shen J-S, Meng X-L, Moore DF, Quirk JM, Shayman JA, Schiffmann R et al (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab\u00a0 95(3):163\u2013168","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10044_CR6","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1590\/S1415-47572012005000031","volume":"35","author":"KB M\u00fcller","year":"2012","unstructured":"M\u00fcller KB, Galdieri LC, Pereira VG, Martins AM, D\u2019Almeida V (2012) Evaluation of oxidative stress markers and cardiovascular risk factors in Fabry Disease patients. Genet Mol Biol 35(2):418\u2013423","journal-title":"Genet Mol Biol"},{"key":"10044_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cca.2016.07.016","volume":"461","author":"GB Biancini","year":"2016","unstructured":"Biancini GB, Jacques CE, Hammerschmidt T, de Souza HM, Donida B, Deon M et al (2016) Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy. Clin Chim Acta\u00a0 461:41\u201346","journal-title":"Clin Chim Acta"},{"issue":"2","key":"10044_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.bbrc.2017.03.030","volume":"486","author":"K-H Chen","year":"2017","unstructured":"Chen K-H, Chou Y-C, Hsiao C-Y, Chien Y, Wang K-L, Lai Y-H et al (2017) Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy. Biochem Biophys Res Commun 486(2):293\u2013299","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10044_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/nep.12977","volume":"22","author":"GB Biancini","year":"2017","unstructured":"Biancini GB, Mor\u00e1s AM, Reinhardt LS, Busatto FF, de Moura Sperotto ND, Saffi J et al (2017) Globotriaosylsphingosine induces oxidative DNA damage in cultured kidney cells. Nephrology (Carlton)\u00a0 22(6):490\u2013493","journal-title":"Nephrology (Carlton)"},{"issue":"11","key":"10044_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3390\/jcm7110409","volume":"7","author":"V Ravarotto","year":"2018","unstructured":"Ravarotto V, Simioni F, Carraro G, Bertoldi G, Pagnin E, Cal\u00f2 L (2018) Oxidative stress and cardiovascular-renal damage in fabry disease: is there room for a pathophysiological involvement? J Clin Med 7(11):409","journal-title":"J Clin Med"},{"issue":"5","key":"10044_CR11","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.4049\/jimmunol.161.5.2524","volume":"161","author":"V Witko-Sarsat","year":"1998","unstructured":"Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeill\u00e8re-Blandin C, Nguyen AT, Canteloup S et al (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161(5):2524\u20132532","journal-title":"J Immunol"},{"issue":"2","key":"10044_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/1354750X.2010.535172","volume":"16","author":"YH Chen","year":"2011","unstructured":"Chen YH, Shi W, Liang XL, Liang YZ, Fu X (2011) Effect of blood sample type on the measurement of advanced oxidation protein products as a biomarker of inflammation and oxidative stress in hemodialysis patients. Biomarkers 16(2):129\u2013135","journal-title":"Biomarkers. marzo"},{"key":"10044_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3109\/10715762.2011.602074","volume":"45","author":"L Selmeci","year":"2011","unstructured":"Selmeci L (2011) Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome? Free Radic Res 45:1115\u20131123","journal-title":"Free Radic Res"},{"issue":"1","key":"10044_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1006\/abio.1996.0292","volume":"239","author":"IFF Benzie","year":"1996","unstructured":"Benzie IFF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of \u00ab antioxidant power \u00bb : The FRAP assay. Anal Biochem 239(1):70\u201376","journal-title":"Anal Biochem"},{"issue":"3","key":"10044_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/112067210301300307","volume":"13","author":"M Nowak","year":"2003","unstructured":"Nowak M, \u015awi\u0229tochowska E, Wielkoszy\u0144ski T, Marek B, Karpe J, G\u00f3rski J et al (2003) Changes in blood antioxidants and several lipid peroxidation products in women with age-related macular degeneration. Eur J Ophthalmol 13(3):281\u2013286","journal-title":"Eur J Ophthalmol"},{"issue":"C","key":"10044_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0076-6879(94)33044-1","volume":"233","author":"ML Hu","year":"1994","unstructured":"Hu ML (1994) Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 233(C):380\u2013385","journal-title":"Methods Enzymol"},{"issue":"2","key":"10044_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/cge.13546","volume":"96","author":"DP Germain","year":"2019","unstructured":"Germain DP, Fouilhoux A, Decramer S, Tardieu M, Pillet P, Fila M et al (2019) Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet 96(2):107\u2013117","journal-title":"Clin Genet"},{"key":"10044_CR18","doi-asserted-by":"publisher","first-page":"100530","DOI":"10.1016\/j.ymgmr.2019.100530","volume":"21","author":"A Kritzer","year":"2019","unstructured":"Kritzer A, Siddharth A, Leestma K, Bodamer O (2019) Early initiation of enzyme replacement therapy in classical Fabry disease normalizes biomarkers in clinically asymptomatic pediatric patients. Mol Genet Metab reports 21:100530","journal-title":"Mol Genet Metab reports"},{"issue":"2","key":"10044_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","volume":"1822","author":"GB Biancini","year":"2012","unstructured":"Biancini GB, Vanzin CS, Rodrigues DB, Deon M, Ribas GS, Barschak AG et al (2012) Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta 1822(2):226\u2013232","journal-title":"Biochim Biophys Acta"},{"key":"10044_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neulet.2016.06.051","volume":"629","author":"C Simoncini","year":"2016","unstructured":"Simoncini C, Chico L, Concolino D, Sestito S, Fancellu L, Boadu W et al (2016) Mitochondrial DNA haplogroups may influence Fabry disease phenotype. Neurosci Lett. 629:58\u201361","journal-title":"Neurosci Lett."},{"key":"10044_CR21","doi-asserted-by":"crossref","unstructured":"Chimenti C, Scopelliti F, Vulpis E, Tafani M, Villanova L, Verardo R, et al (2015) Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy. Hum Pathol 46(11):1760\u20131768","DOI":"10.1016\/j.humpath.2015.07.017"},{"issue":"9","key":"10044_CR22","doi-asserted-by":"publisher","first-page":"e0204618","DOI":"10.1371\/journal.pone.0204618","volume":"13","author":"V Ravarotto","year":"2018","unstructured":"Ravarotto V, Carraro G, Pagnin E, Bertoldi G, Simioni F, Maiolino G et al (2018) Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling? PLoS One 13(9):e0204618","journal-title":"PLoS One"},{"issue":"1","key":"10044_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/ki.2013.520","volume":"86","author":"L Shu","year":"2014","unstructured":"Shu L, Vivekanandan-Giri A, Pennathur S, Smid BE, Aerts JMFG, Hollak CEM et al (2014) Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease. Kidney Int 86(1):58\u201366","journal-title":"Kidney Int"},{"issue":"4","key":"10044_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","volume":"52","author":"BE Smid","year":"2015","unstructured":"Smid BE, Van der Tol L, Biegstraaten M, Linthorst GE, Hollak CEM, Poorthuis BJHM (2015) Plasma globotriaosylsphingosine in relation to phenotypes of fabry disease. J Med Genet 52(4):262\u2013268","journal-title":"J Med Genet"},{"issue":"6","key":"10044_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/humu.10275","volume":"22","author":"M Yasuda","year":"2003","unstructured":"Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ (2003) Fabry disease: characterization of \u03b1-galactoslidase a double mutations and the D313Y Plasma enzyme pseudodeficiency allele. Hum Mutat 22(6):486\u2013492","journal-title":"Hum Mutat"},{"issue":"3","key":"10044_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","volume":"80","author":"R Froissart","year":"2003","unstructured":"Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I (2003) Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 80(3):307\u2013314","journal-title":"Mol Genet Metab"},{"issue":"6","key":"10044_CR27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1161\/CIRCGENETICS.113.000578","volume":"7","author":"JR Golbus","year":"2014","unstructured":"Golbus JR, Puckelwartz MJ, Dellefave-Castillo L, Fahrenbach JP, Nelakuditi V, Pesce LL et al (2014) Targeted analysis of whole genome sequence data to diagnose genetic cardiomyopathy. Circ Cardiovasc Genet 7(6):751\u2013759","journal-title":"Circ Cardiovasc Genet"},{"issue":"2","key":"10044_CR28","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","volume":"114","author":"S Ferreira","year":"2015","unstructured":"Ferreira S, Ortiz A, Germain DP, Viana-Baptista M, Caldeira-Gomes A, Camprecios M et al (2015) The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. Mol Genet Metab 114(2):248\u2013258","journal-title":"Mol Genet Metab"},{"key":"10044_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/jhg.2012.32","volume":"57","author":"LT Tura\u00e7a","year":"2012","unstructured":"Tura\u00e7a LT, Pessoa JG, Motta FL, Mu\u00f1oz Rojas MV, M\u00fcller KB, Louren\u00e7o CM et al (2012) New mutations in the GLA gene in Brazilian families with Fabry disease. J Hum Genet 57:347\u2013351","journal-title":"J Hum Genet"},{"issue":"3","key":"10044_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","volume":"126","author":"DP Germain","year":"2019","unstructured":"Germain DP, Arad M, Burlina A, Elliott PM, Falissard B, Feldt-Rasmussen U et al (2019) The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease\u2014a systematic literature review by a European panel of experts. Mol Genet Metab 126(3):224\u2013235","journal-title":"Mol Genet Metab"},{"key":"10044_CR31","first-page":"100454","volume":"19","author":"DP Germain","year":"2019","unstructured":"Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A et al (2019) The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep 19:100454","journal-title":"Mol Genet Metab Rep Giugno"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10044-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10044-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10044-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T18:23:37Z","timestamp":1696443817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10044-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10044"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10044-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this paper","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The authors report no disclosures relevant to the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}